|
|
News Breaks
|
November 5, 2009
|
| 08:10 EDT |  | SNSS |
| theflyonthewall.com: | Sunesis' Voreloxin receives FDA orphan drug designation | | The FDA has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia. Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML. :theflyonthewall.com |
|
|
News For SNSS From The Last 14 Days Check below for free stories on SNSS the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 2, 2012
|
| 16:08 EDT | | SNSS |
|
|
|
|
|
Subscribe for More Information